Back to top
more

Vanda Pharmaceuticals (VNDA)

(Delayed Data from NSDQ)

$5.00 USD

5.00
668,295

-0.10 (-1.96%)

Updated Nov 15, 2024 04:00 PM ET

After-Market: $5.00 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks News

GW Pharma (GWPH) Posts Narrower-than-Expected Q4 Loss

GW Pharmaceuticals (GWPH) reported a narrower-than-expected loss of 89 cents per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016).

    Novo Nordisk Files Regulatory Application for Semaglutide

    Novo Nordisk (NVO) submitted regulatory application for semaglutide in both the U.S. and the EU for the treatment of adults with type II diabetes.

      Acceleron, Celgene Present Myelodysplastic Syndromes Data

      Acceleron (XLRN) and Celgene (CELG) announced updated data from the ongoing phase II studies on luspatercept in myelodysplastic syndromes patients.

        Alnylam Reports Positive Data on Fitusiran, Givosiran

        Alnylam (ALNY) announced new positive data from an ongoing phase II OLE study on fitusiran for the treatment of patients with hemophilia A or B, without inhibitors.

          Pfizer (PFE) Presents Favorable Data on Leukemia Candidate

          Pfizer Inc. (PFE) announced new positive data from a randomized phase II study on its investigational candidate glasdegib (PF-04449913) for the first-line treatment of patients with acute myeloid leukemia (AML).

            Incyte Jakafi Positive in Pooled Analysis of Five-Year Data

            Incyte (INCY) announced pooled analysis of five-year data from two phase III studies on Jakafi, which support previous long-term results.

              Alexion Presents Data from Ultra-Rare Blood Disorder Study

              Alexion Pharmaceuticals (ALXN) presented new data from a dose-escalation study on ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria at ASH.

                Pfizer Offers Positive Phase III Data on Pediatric Epilesy Drug

                Pfizer Inc. (PFE) announced positive top-line results from a phase III study evaluating its marketed drug, Lyrica (pregabalin), as adjunctive therapy for the treatment of pediatric patients suffering from epilepsy with partial-onset seizures.

                  bluebird Stock Up on Positive Interim Multiple Myeloma Data

                  bluebird bio (BLUE) reported encouraging interim phase I data on its anti-BCMA CAR T cell candidate, bb2121, in relapsed/refractory multiple myeloma patients.

                    Merck KGaA (MKGAF) Expands Distribution Deal with Roche

                    Merck (MKGAF) announced that it has expanded the distribution alliance with Roche (RHHBY) to include enzyme products ??? PCR and qPCR.

                      Heat Biologics Stock Falls on Negative Bladder Cancer Data

                      Heat Biologics (HTBX) presented disappointing top-line phase II data from the bladder cancer study on its lead pipeline candidate, HS-410.

                        AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.

                        AbbVie Inc. (ABBV) announced that the FDA has granted Orphan Drug Designation to its investigational IL-23 inhibitor, risankizumab (ABBV-066; formerly BI 655066), for the treatment of Crohn's disease in pediatric patients.

                          Ultragenyx (RARE) Reports Positive Phase II Study on UX007

                          Ultragenyx (RARE) announced positive data from a phase II study on UX007 for the treatment of patients with long-chain fatty acid oxidation disorder (LC-FAOD).

                            Agenus' INCAGN1876 in Phase I/II Study for Solid Tumors

                            Agenus (AGEN) announced that it has dosed the first patient in a phase I/II study on INCAGN1949 for the treatment of patients with solid tumors.

                              Cytori Scleroderma Study Two-Year Follow-Up Data Published

                              Cytori Therapeutics (CYTX) announced the publication of two year follow-up data from the scleroderma study.

                                Novo Nordisk's Tresiba Shows Safe Cardiovascular Profile

                                Novo Nordisk (NVO) announced headline results from the DEVOTE study that confirmed the cardiovascular safety of Tresiba, in comparison to Sanofi???s (SNY) Lantus.

                                  PhaseRx Soars on Orphan Drug Status for Rare Liver Disease

                                  PhaseRx (PZRX) received Orphan Drug status from the FDA for PRX-OTC for the treatment of rare liver disorder.

                                    Amicus Provides Regulatory Update on Fabry Disease Drug

                                    Amicus Therapeutics, Inc. (FOLD) issued an update on the regulatory pathway for migalastat for the treatment of Fabry disease in the U.S.

                                      Mallinckrodt (MNK) Tops Q4 Earnings on Solid Sales Growth

                                      Mallinckrodt Public Limited Company (MNK) reported adjusted earnings of $2.04 per share in the fourth quarter of fiscal 2016 (ended Sep 30, 2016), beating the Zacks Consensus Estimate of $1.98.

                                        Zacks.com featured highlights: Electronic Arts, Vanda Pharmaceuticals, Advanced Energy Industries, Community Bank System and Lancaster Colony

                                        Zacks.com featured highlights: Electronic Arts, Vanda Pharmaceuticals, Advanced Energy Industries, Community Bank System and Lancaster Colony